This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Measure of benefits used in the economic analysis
The main measure of health benefit used was the QALYs. The utility levels were derived from the results of published studies. The methods of valuation used in the primary studies from which the utility estimate was derived were not reported.
Direct costs
The study employed the direct costs to the hospital. These included the laboratory cost of MS/MS, the cost-savings associated with a presymptomatic diagnosis and diagnosis after symptoms manifested, the cost of a false-positive test, the cost of inpatient stay following early and late detection of IEM, and dietary costs for children with IEM. The dietary costs were for disease-specific feeding formula for children aged 0 to 4 years, and a special diet for children aged 5 years and older. The resource quantities were not reported separately from the costs. The cost data were derived from studies published studies between 1999 and 2001, and charge data from commercial laboratories. The costs were discounted at a rate of 3% per annum. The study reported average and incremental costs. The price year was not reported.
Statistical analysis of costs
The costs were treated deterministically. This was appropriate for some of the cost estimates (e.g. unit cost of a screening test), but other costs (e.g. length of inpatient stay) typically exhibited high variation both within and between centres. The failure to reflect this variation could reduce the applicability and generalisability of the results.
Indirect Costs
The indirect costs were not included in the analysis. No justification was given for this omission, but it can be inferred that it was due to the study perspective being that of a large HMO rather than societal.
Currency

US dollars ($).
Sensitivity analysis
A sensitivity analysis was carried out on the laboratory cost of the screening test, the rate of false-positive test results, and the effects of early detection on mortality and morbidity. The laboratory cost of the screening test was assumed to be $7 in the most favourable scenario and $20 in the least favourable scenario. The increase in life expectancy associated with early detection of IEM, compared with late detection, was assumed to be 25 years in the most favourable scenario and 15 years in the least favourable scenario. The method used to select the ranges explored in the sensitivity analysis was not reported. The ranges used for the rate of false-positive test results and the effect of early detection on morbidity were unclear. The sensitivity analysis explored variability in the data using a multi-way analysis of extremes.
